Protective immunity induced by a recombinant BCG vaccine encoding the cyclophilin gene of Toxoplasma gondii

Qinlei Yu, Xiangsheng Huang, Pengtao Gong, Qian Zhang, Jianhua Li, Guocai Zhang, Ju Yang, He Li, Nan Wang, Xichen Zhang

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The investigation of Toxoplasma gondii virulence factors can elucidate the immunopathology of T. gondii infection and identify potential candidates for effective human vaccines. The adjuvant is an important component of an effective vaccine. In this study, attenuated Mycobacterium bovis was used as a live vaccine vector with both antigen and adjuvant characteristics. Following amplification of the T. gondii cyclophilin gene, the shuttle expression plasmid pMV261-TgCyP and integrative expression plasmid pMV361-TgCyP were constructed, and their expression was stimulated after transfection into BCG. Both recombinant plasmids were highly immunogenic. Greater proliferation of CD4+ and CD8+ T cells was observed in the rBCG-vaccinated groups compared to the control groups. The levels of Th1-type IFN-γ, IL-2 and IL-12 were significantly increased following immunisation with the rBCG vaccines via the i.v. or oral route, which indicated that catalytic activity against T. gondii infection was generated in the mice. rBCGpMV361-TgCyP i.v. inoculation resulted in a higher protection efficiency, as demonstrated by the increased survival time and survival rate (17%) of BALB/c mice. The present study demonstrates that a BCG vector expressing a target antigen, TgCyP, represent an alternative system for the production of effective vaccines to prevent toxoplasmosis.

Original languageEnglish (US)
Pages (from-to)6065-6071
Number of pages7
JournalVaccine
Volume31
Issue number51
DOIs
StatePublished - Dec 9 2013
Externally publishedYes

Fingerprint

BCG vaccine
cyclophilins
Cyclophilins
BCG Vaccine
Synthetic Vaccines
Toxoplasma
recombinant vaccines
Toxoplasma gondii
Immunity
Vaccines
immunity
vaccines
Toxoplasmosis
plasmids
Mycobacterium bovis
Plasmids
Genes
adjuvants
genes
immunopathology

Keywords

  • BALB/c
  • Cyclophilin
  • RBCG
  • T. gondii

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Protective immunity induced by a recombinant BCG vaccine encoding the cyclophilin gene of Toxoplasma gondii. / Yu, Qinlei; Huang, Xiangsheng; Gong, Pengtao; Zhang, Qian; Li, Jianhua; Zhang, Guocai; Yang, Ju; Li, He; Wang, Nan; Zhang, Xichen.

In: Vaccine, Vol. 31, No. 51, 09.12.2013, p. 6065-6071.

Research output: Contribution to journalArticle

Yu, Q, Huang, X, Gong, P, Zhang, Q, Li, J, Zhang, G, Yang, J, Li, H, Wang, N & Zhang, X 2013, 'Protective immunity induced by a recombinant BCG vaccine encoding the cyclophilin gene of Toxoplasma gondii', Vaccine, vol. 31, no. 51, pp. 6065-6071. https://doi.org/10.1016/j.vaccine.2013.10.015
Yu, Qinlei ; Huang, Xiangsheng ; Gong, Pengtao ; Zhang, Qian ; Li, Jianhua ; Zhang, Guocai ; Yang, Ju ; Li, He ; Wang, Nan ; Zhang, Xichen. / Protective immunity induced by a recombinant BCG vaccine encoding the cyclophilin gene of Toxoplasma gondii. In: Vaccine. 2013 ; Vol. 31, No. 51. pp. 6065-6071.
@article{03a2633d83d24f31a77e0acd6df56a14,
title = "Protective immunity induced by a recombinant BCG vaccine encoding the cyclophilin gene of Toxoplasma gondii",
abstract = "The investigation of Toxoplasma gondii virulence factors can elucidate the immunopathology of T. gondii infection and identify potential candidates for effective human vaccines. The adjuvant is an important component of an effective vaccine. In this study, attenuated Mycobacterium bovis was used as a live vaccine vector with both antigen and adjuvant characteristics. Following amplification of the T. gondii cyclophilin gene, the shuttle expression plasmid pMV261-TgCyP and integrative expression plasmid pMV361-TgCyP were constructed, and their expression was stimulated after transfection into BCG. Both recombinant plasmids were highly immunogenic. Greater proliferation of CD4+ and CD8+ T cells was observed in the rBCG-vaccinated groups compared to the control groups. The levels of Th1-type IFN-γ, IL-2 and IL-12 were significantly increased following immunisation with the rBCG vaccines via the i.v. or oral route, which indicated that catalytic activity against T. gondii infection was generated in the mice. rBCGpMV361-TgCyP i.v. inoculation resulted in a higher protection efficiency, as demonstrated by the increased survival time and survival rate (17{\%}) of BALB/c mice. The present study demonstrates that a BCG vector expressing a target antigen, TgCyP, represent an alternative system for the production of effective vaccines to prevent toxoplasmosis.",
keywords = "BALB/c, Cyclophilin, RBCG, T. gondii",
author = "Qinlei Yu and Xiangsheng Huang and Pengtao Gong and Qian Zhang and Jianhua Li and Guocai Zhang and Ju Yang and He Li and Nan Wang and Xichen Zhang",
year = "2013",
month = "12",
day = "9",
doi = "10.1016/j.vaccine.2013.10.015",
language = "English (US)",
volume = "31",
pages = "6065--6071",
journal = "Vaccine",
issn = "0264-410X",
publisher = "Elsevier BV",
number = "51",

}

TY - JOUR

T1 - Protective immunity induced by a recombinant BCG vaccine encoding the cyclophilin gene of Toxoplasma gondii

AU - Yu, Qinlei

AU - Huang, Xiangsheng

AU - Gong, Pengtao

AU - Zhang, Qian

AU - Li, Jianhua

AU - Zhang, Guocai

AU - Yang, Ju

AU - Li, He

AU - Wang, Nan

AU - Zhang, Xichen

PY - 2013/12/9

Y1 - 2013/12/9

N2 - The investigation of Toxoplasma gondii virulence factors can elucidate the immunopathology of T. gondii infection and identify potential candidates for effective human vaccines. The adjuvant is an important component of an effective vaccine. In this study, attenuated Mycobacterium bovis was used as a live vaccine vector with both antigen and adjuvant characteristics. Following amplification of the T. gondii cyclophilin gene, the shuttle expression plasmid pMV261-TgCyP and integrative expression plasmid pMV361-TgCyP were constructed, and their expression was stimulated after transfection into BCG. Both recombinant plasmids were highly immunogenic. Greater proliferation of CD4+ and CD8+ T cells was observed in the rBCG-vaccinated groups compared to the control groups. The levels of Th1-type IFN-γ, IL-2 and IL-12 were significantly increased following immunisation with the rBCG vaccines via the i.v. or oral route, which indicated that catalytic activity against T. gondii infection was generated in the mice. rBCGpMV361-TgCyP i.v. inoculation resulted in a higher protection efficiency, as demonstrated by the increased survival time and survival rate (17%) of BALB/c mice. The present study demonstrates that a BCG vector expressing a target antigen, TgCyP, represent an alternative system for the production of effective vaccines to prevent toxoplasmosis.

AB - The investigation of Toxoplasma gondii virulence factors can elucidate the immunopathology of T. gondii infection and identify potential candidates for effective human vaccines. The adjuvant is an important component of an effective vaccine. In this study, attenuated Mycobacterium bovis was used as a live vaccine vector with both antigen and adjuvant characteristics. Following amplification of the T. gondii cyclophilin gene, the shuttle expression plasmid pMV261-TgCyP and integrative expression plasmid pMV361-TgCyP were constructed, and their expression was stimulated after transfection into BCG. Both recombinant plasmids were highly immunogenic. Greater proliferation of CD4+ and CD8+ T cells was observed in the rBCG-vaccinated groups compared to the control groups. The levels of Th1-type IFN-γ, IL-2 and IL-12 were significantly increased following immunisation with the rBCG vaccines via the i.v. or oral route, which indicated that catalytic activity against T. gondii infection was generated in the mice. rBCGpMV361-TgCyP i.v. inoculation resulted in a higher protection efficiency, as demonstrated by the increased survival time and survival rate (17%) of BALB/c mice. The present study demonstrates that a BCG vector expressing a target antigen, TgCyP, represent an alternative system for the production of effective vaccines to prevent toxoplasmosis.

KW - BALB/c

KW - Cyclophilin

KW - RBCG

KW - T. gondii

UR - http://www.scopus.com/inward/record.url?scp=84888434248&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888434248&partnerID=8YFLogxK

U2 - 10.1016/j.vaccine.2013.10.015

DO - 10.1016/j.vaccine.2013.10.015

M3 - Article

C2 - 24176493

AN - SCOPUS:84888434248

VL - 31

SP - 6065

EP - 6071

JO - Vaccine

JF - Vaccine

SN - 0264-410X

IS - 51

ER -